t
Scancell Holdings plc announced on 3 April 2024 that certain employees exercised options over 160,000 ordinary shares in the Company. An application has been made for these shares to be admitted to trading on AIM. This admission is expected to become effective at 8:00 a.m. on 4 April 2024.
| Date | 3 Apr 2024 |
| Time | 07:00:06 |
| Category | Capital structure |
| ID | 0450J |
3 April 2024
Scancell Holdings plc
("Scancell" or the "Company")
Employee exercise of share options
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, announces that certain employees of the Company have exercised their options over 160,000 ordinary shares in the Company.
An application has been made to London Stock Exchange plc for these shares to be admitted to trading on AIM and it is expected that this will become effective at 8.00 a.m. on 4 April 2024.
|
For further information, please contact: |
|
|
|
|
|
Scancell Holdings plc |
+44 (0) 20 3709 5700 |
|
Professor Lindy Durrant, CEO Dr Jean-Michel Cosséry, Non-Executive Chairman
|
|
|
Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker) |
+44 (0) 20 7710 7600 |
|
Nicholas Moore/Samira Essebiyea (Healthcare Investment Banking) Nick Adams/Nick Harland (Corporate Broking) |
|
|
Panmure Gordon (UK) Limited (Joint Broker) |
+44 (0) 20 7886 2500 |
|
Freddy Crossley/Emma Earl (Corporate Finance) |
|
|
Rupert Dearden (Corporate Broking) |
|
|
WG Partners LLP (Joint Broker) |
+44 (0) 20 3705 9330 |
|
David Wilson/Claes Spang/Sathesh Nadarajah/Erland Sternby |
|
|
ICR Consilium |
+44 (0) 20 3709 5700 |
|
Mary-Jane Elliott/Angela Gray/Lindsey Neville |
|
About Scancell
Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope® and ImmunoBody® for vaccines and GlyMab® and AvidiMab® for antibodies.
Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope® and ImmunoBody®) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab®) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab®).
For further information about Scancell, please visit: https://www.scancell.co.uk/